ArticleThe Kaohsiung journal of medical sciences2026
Fat Mass and Obesity-Associated Protein Contributes to Tumorigenesis and Drug Resistance of Diffuse Large B-Cell Lymphoma by Suppressing N6-Methyladenosine Methylation of Myc.
Article in The Kaohsiung journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Reader-dependent functional duality of FTO: a context-switching node at the intersection of immune evasion and therapeutic resistance.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ibrutinib resistance remains a major obstacle in the treatment of diffuse large B-cell lymphoma (DLBCL). Fat mass and obesity-associated protein (FTO) has been implicated in drug resistance through its regulation of N6-methyladenosine (m6A) modifications; however, whether FTO mediates ibrutinib resistance in DLBCL remains unclear. In this study, we found that FTO expression was significantly upregulated in patient samples and DLBCL cell lines. Functional assays showed that FTO knockout or knockdown suppressed cell proliferation and colony formation, whereas FTO overexpression promoted tumor growth and increased ibrutinib half-maximal inhibitory concentration. Mechanistically, FTO directly bound to myelocytomatosis oncogene (Myc) mRNA and removed m6A modifications, stabilizing Myc transcripts and enhancing Myc protein expression. Methylated RNA immunoprecipitation-quantitative polymerase chain reaction confirmed that FTO knockout increased m6A enrichment on Myc mRNA, leading to decreased Myc stability. Rescue experiments showed that reintroducing Myc partially restored the proliferative and drug-resistant phenotype of FTO-deficient cells. Consistently, in xenograft models, FTO promoted tumor growth and ibrutinib resistance in a manner partly dependent on Myc. Overall, FTO promotes DLBCL progression and ibrutinib resistance by demethylating Myc mRNA and stabilizing its expression. These findings highlight the FTO-m6A-Myc axis as a potential therapeutic target for overcoming drug resistance in DLBCL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.